Certara Launches Phoenix™ Version 8.5 Drug Development Software Blog Post
RADNOR, PA – 2024 年 8 月 15 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5. Phoenix is the pharmaceutical…
Certara Research Reveals IRA’s Impact on Biosimilar Uptake Blog Post
RADNOR, PA – 2024 年 8 月 15 日 — Certara, Inc., a global leader in model-informed drug development, has published new research on the impact of the Inflation Reduction Act (IRA) on…
Medicines that matter: Biohaven’s Nurtec™ drug development journey Blog Post
2020 年 2 月，Biohaven 制药公司宣布，美国食品和药物管理局（FDA）批准 Nurtec™ （Rimegepant）用于成人偏头痛的急性治疗。2021 年 5 月，FDA 还批准了...
All you need to know about NCI, CDISC and SDTM controlled terminology Blog Post
The use of controlled terminology (CT) is vital to successful clinical study build. In clinical trials, CT can be referred to in several different ways, such as: While these terms…
Model-Informed Confidence in Oncology Dose Selection Blog Post
Discover an oncology-focused company that gained confidence in their dose selection for an AML trial with pediatric patients and reduced their clinical development costs, by using mechanistic modeling. Sutro is...
Pinnacle 21 Enterprise: Dataset Validation & Submission Readiness Blog Post
探索 Pinnacle 21 Enterprise 如何简化数据集验证、提升合规性并助您做好提交准备。
Digital Payer Portals for Enhanced Value Communication Blog Post
The trend of using digital tools for communication and information sharing in the life science industry has gained traction. Market access professionals work differently today. This shift began over the…
